Solid Biosciences (SLDB) EBIT (2017 - 2026)

Solid Biosciences has reported EBIT for 10 years, with the latest figure at -$57.3 million in Q1 2026.

• Quarterly EBIT fell 43.08% year-over-year to -$57.3 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$196.5 million (down 37.46% YoY) and the FY2025 annual result came in at -$179.2 million, down 38.14% from the prior year.
• EBIT slipped to -$57.3 million in Q1 2026 per SLDB's latest filing, from -$49.4 million in the prior quarter.
• Over five years, EBIT peaked at -$21.1 million in Q3 2022 and troughed at -$57.3 million in Q1 2026.
• A 5-year average of -$33.9 million and a median of -$32.0 million in 2023 frame the typical range for EBIT.
• The sharpest annual moves came in 2022 and 2023: EBIT slumped 85.32% in 2022, then soared 35.59% in 2023.
• Over 5 years, EBIT stood at -$34.6 million in 2022, then jumped by 35.59% to -$22.3 million in 2023, then plunged by 79.19% to -$39.9 million in 2024, then decreased by 23.83% to -$49.4 million in 2025, then decreased by 16.0% to -$57.3 million in 2026.
• According to Business Quant data, EBIT over the past three periods registered -$57.3 million, -$49.4 million, and -$48.1 million for Q1 2026, Q4 2025, and Q3 2025 respectively.